Manuela Ferracin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3159397/publications.pdf

Version: 2024-02-01

204 papers

32,239 citations

23567

h-index

4548

171 g-index

213 all docs

213 docs citations

213 times ranked

32784 citing authors

#	Article	IF	CITATIONS
1	Overexpression of ultraconserved region 83- induces lung cancer tumorigenesis. PLoS ONE, 2022, 17, e0261464.	2.5	4
2	Sickle Cell Trait and SARS-CoV-2-Induced Rhabdomyolysis: A Case Report. American Journal of Case Reports, 2022, 23, e934220.	0.8	0
3	Circulating miR-320b and miR-483-5p levels are associated with COVID-19 in-hospital mortality. Mechanisms of Ageing and Development, 2022, 202, 111636.	4.6	15
4	Pathophysiology roles and translational opportunities of miRNAs in cutaneous melanoma. , 2022, , 339-384.		0
5	microRNAs and Inflammatory Immune Response in SARS-CoV-2 Infection: A Narrative Review. Life, 2022, 12, 288.	2.4	10
6	Circulating microRNA biomarkers in melanoma and non-melanoma skin cancer. Expert Review of Molecular Diagnostics, 2022, 22, 305-318.	3.1	12
7	The autocrine loop of ALK receptor and ALKAL2 ligand is an actionable target in consensus molecular subtype 1 colon cancer. Journal of Experimental and Clinical Cancer Research, 2022, 41, 113.	8.6	9
8	Dysplastic nevi and melanoma: microRNAs tell a divergent story. Pathology Research and Practice, 2022, , 153942.	2.3	0
9	Decreased serum levels of the inflammaging marker miR-146a are associated with clinical non-response to tocilizumab in COVID-19 patients. Mechanisms of Ageing and Development, 2021, 193, 111413.	4.6	89
10	Method for the Detection of the Cleaved Form of Shiga Toxin 2a Added to Normal Human Serum. Toxins, 2021, 13, 94.	3.4	2
11	Cancer of Unknown Primary: Challenges and Progress in Clinical Management. Cancers, 2021, 13, 451.	3.7	24
12	Preliminary results from whole-genome expression analysis in patients with secondary adrenal insufficiency treated with modified-release hydrocortisone. Endocrine, 2021, 73, 177-185.	2.3	1
13	Circulating microRNA-23b-3p and tissue microRNA-193a-3p as promising molecular biomarkers in human hepatocellular carcinoma. Digestive and Liver Disease, 2021, 53, S38.	0.9	O
14	Unraveling the role of microRNA/isomiR network in multiple primary melanoma pathogenesis. Cell Death and Disease, 2021, 12, 473.	6.3	13
15	Genetic Characterization of Cancer of Unknown Primary Using Liquid Biopsy Approaches. Frontiers in Cell and Developmental Biology, 2021, 9, 666156.	3.7	12
16	MicroRNA expression profiling with a droplet digital PCR assay enables molecular diagnosis and prognosis of cancers of unknown primary. Molecular Oncology, 2021, 15, 2732-2751.	4.6	14
17	Longitudinal Circulating Levels of miR-23b-3p, miR-126-3p and IncRNA GAS5 in HCC Patients Treated with Sorafenib. Biomedicines, 2021, 9, 813.	3.2	11
18	Activation of Endogenous Retrovirus, Brain Infections and Environmental Insults in Neurodegeneration and Alzheimer's Disease. International Journal of Molecular Sciences, 2021, 22, 7263.	4.1	15

#	Article	lF	Citations
19	Non-coding RNA dysregulation in skin cancers. Essays in Biochemistry, 2021, 65, 641-655.	4.7	12
20	The Non-Coding RNA Journal Club: Highlights on Recent Papers—9. Non-coding RNA, 2021, 7, 58.	2.6	1
21	MicroRNA Isoforms Contribution to Melanoma Pathogenesis. Non-coding RNA, 2021, 7, 63.	2.6	6
22	Newly-Discovered Neural Features Expand the Pathobiological Knowledge of Blastic Plasmacytoid Dendritic Cell Neoplasm. Cancers, 2021, 13, 4680.	3.7	6
23	Clinical histopathological features and CDKN2A/CDK4/MITF mutational status of patients with multiple primary melanomas from Bologna: Italy is a fascinating but complex mosaic. Italian Journal of Dermatology and Venereology, 2021, 156, 599-605.	0.2	3
24	P2X7 promotes metastatic spreading and triggers release of miRNA-containing exosomes and microvesicles from melanoma cells. Cell Death and Disease, 2021, 12, 1088.	6.3	31
25	Circulating miR-184 is a potential predictive biomarker of cardiac damage in Anderson–Fabry disease. Cell Death and Disease, 2021, 12, 1150.	6.3	6
26	Particulate Shiga Toxin 2 in Blood is Associated to the Development of Hemolytic Uremic Syndrome in Children. Thrombosis and Haemostasis, 2020, 120, 107-120.	3.4	16
27	Basal Cell Carcinoma: A Comprehensive Review. International Journal of Molecular Sciences, 2020, 21, 5572.	4.1	73
28	MicroRNA profiling of blastic plasmacytoid dendritic cell neoplasm and myeloid sarcoma. Hematological Oncology, 2020, 38, 831-833.	1.7	1
29	The Long Noncoding RNA CCAT2 Induces Chromosomal Instability Through BOP1-AURKB Signaling. Gastroenterology, 2020, 159, 2146-2162.e33.	1.3	75
30	The Clinical Utility of miR-21 and let-7 in Non-small Cell Lung Cancer (NSCLC). A Systematic Review and Meta-Analysis. Frontiers in Oncology, 2020, 10, 516850.	2.8	23
31	The Sda Synthase B4GALNT2 Reduces Malignancy and Stemness in Colon Cancer Cell Lines Independently of Sialyl Lewis X Inhibition. International Journal of Molecular Sciences, 2020, 21, 6558.	4.1	11
32	Long-term exposure of human endothelial cells to metformin modulates miRNAs and isomiRs. Scientific Reports, 2020, 10, 21782.	3.3	14
33	MiR-30e-3p Influences Tumor Phenotype through <i>MDM2</i> /i>/ <i>TP53</i> Axis and Predicts Sorafenib Resistance in Hepatocellular Carcinoma. Cancer Research, 2020, 80, 1720-1734.	0.9	47
34	Small extracellular vesicles deliver miRâ€21 and miRâ€217 as proâ€senescence effectors to endothelial cells. Journal of Extracellular Vesicles, 2020, 9, 1725285.	12.2	104
35	Impaired Innate Immunity Mechanisms in the Brain of Alzheimer's Disease. International Journal of Molecular Sciences, 2020, 21, 1126.	4.1	13
36	BRAF, KIT, and NRAS Mutations of Acral Melanoma in White Patients. American Journal of Clinical Pathology, 2020, 153, 664-671.	0.7	18

#	Article	IF	Citations
37	Defining the Prognostic Role of MicroRNAs in Cutaneous Melanoma. Journal of Investigative Dermatology, 2020, 140, 2260-2267.	0.7	15
38	High Expression of the Sda Synthase B4GALNT2 Associates with Good Prognosis and Attenuates Stemness in Colon Cancer. Cells, 2020, 9, 948.	4.1	13
39	Targeting p53 and histone methyltransferases restores exhausted CD8+ T cells in HCV infection. Nature Communications, 2020, 11 , 604 .	12.8	44
40	Abstract 5432: Cancer of unknown primary site-of-origin: An enigma ready to be miR-solved., 2020,,.		0
41	Abstract 5361: Isolation and genetic characterization of circulating tumor cells from cancer of unknown primary. , 2020, , .		0
42	Abstract 1417: Development of a miRNA-based prediction tool to discriminate cutaneous blastic plasmacytoid dendritic cell neoplasm from cutaneous myeloid sarcoma. , 2020, , .		0
43	Abstract 4833: Unraveling the role of microRNAs in multiple primary melanoma pathogenesis. , 2020, , .		0
44	Expression profiles of the internal jugular and saphenous veins: Focus on hemostasis genes. Thrombosis Research, 2020, 191, 113-124.	1.7	3
45	Bone sarcoma patient-derived xenografts are faithful and stable preclinical models for molecular and therapeutic investigations. Scientific Reports, 2019, 9, 12174.	3.3	52
46	Impact of sialyltransferase ST6GAL1 overexpression on different colon cancer cell types. Glycobiology, 2019, 29, 684-695.	2.5	22
47	Reprogramming of Amino Acid Transporters to Support Aspartate and Glutamate Dependency Sustains Endocrine Resistance in Breast Cancer. Cell Reports, 2019, 28, 104-118.e8.	6.4	67
48	The extensive role of miR-155 in malignant and non-malignant diseases. Molecular Aspects of Medicine, 2019, 70, 33-56.	6.4	33
49	Exosomes from CD99-deprived Ewing sarcoma cells reverse tumor malignancy by inhibiting cell migration and promoting neural differentiation. Cell Death and Disease, 2019, 10, 471.	6.3	23
50	The Non-Coding RNA Journal Club: Highlights on Recent Papers—7. Non-coding RNA, 2019, 5, 40.	2.6	2
51	DNA methylation of shelf, shore and open sea CpG positions distinguish high microsatellite instability from low or stable microsatellite status colon cancer stem cells. Epigenomics, 2019, 11, 587-604.	2.1	29
52	KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic non-squamous NSCLC. Annals of Oncology, 2019, 30, ii55-ii56.	1.2	1
53	MicroRNA-Based Prophylaxis in a Mouse Model of Cirrhosis and Liver Cancer. Molecular Therapy - Nucleic Acids, 2019, 14, 239-250.	5.1	14
54	Genetic dynamics in untreated CLL patients with either stable or progressive disease: a longitudinal study. Journal of Hematology and Oncology, 2019, 12, 114.	17.0	5

#	Article	IF	Citations
55	KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591988554.	3.2	25
56	Estrogen Receptors and Melanoma: A Review. Cells, 2019, 8, 1463.	4.1	41
57	Genomic stability, anti-inflammatory phenotype, and up-regulation of the RNAseH2 in cells from centenarians. Cell Death and Differentiation, 2019, 26, 1845-1858.	11.2	37
58	Interplay between small and long nonâ€coding <scp>RNA</scp> s in cutaneous melanoma: a complex jigsaw puzzle with missing pieces. Molecular Oncology, 2019, 13, 74-98.	4.6	29
59	Abstract 1805: Integrative analysis of microRNAs in blastic plasmacytoid dendritic cell neoplasm. , 2019,		0
60	Epigenetic and epitranscriptomic changes in colorectal cancer: Diagnostic, prognostic, and treatment implications. Cancer Letters, 2018, 419, 84-95.	7.2	52
61	Quantification of Circulating MicroRNAs by Droplet Digital PCR. Methods in Molecular Biology, 2018, 1768, 445-457.	0.9	21
62	Cancer-associated rs6983267 SNP and its accompanying long noncoding RNA <i>CCAT2</i> induce myeloid malignancies via unique SNP-specific RNA mutations. Genome Research, 2018, 28, 432-447.	5.5	58
63	LncRNAs as novel players in hepatocellular carcinoma recurrence. Oncotarget, 2018, 9, 35085-35099.	1.8	46
64	Cancer Site-Specific Multiple microRNA Quantification by Droplet Digital PCR. Frontiers in Oncology, 2018, 8, 447.	2.8	15
65	Heterotopic auxiliary segment 2–3 liver transplantation with delayed total hepatectomy: New strategies for nonresectable colorectal liver metastases. Surgery, 2018, 164, 601-603.	1.9	20
66	Essential role of MED1 in the transcriptional regulation of ER-dependent oncogenic miRNAs in breast cancer. Scientific Reports, 2018, 8, 11805.	3.3	10
67	Heart rate reduction with ivabradine in the early phase of atherosclerosis is protective in the endothelium of ApoE-deficient mice. Journal of Physiology and Pharmacology, 2018, 69, 35-52.	1.1	18
68	Abstract 2079: Collection of patient-derived xenografts (PDX) to study the biology and therapy of bone sarcomas. , 2018, , .		0
69	Abstract 3313: Epigenetic biomarkers of prognosis in stage IIA colon cancer. Cancer Research, 2018, 78, 3313-3313.	0.9	1
70	Abstract 3549: Exosome-mediated transfer of sh-CD99 is sufficient to modulate cell differentiation in Ewing sarcoma. , $2018, , .$		0
71	Is autopsy tissue a valid control for epilepsy surgery tissue in micro <scp>RNA</scp> studies?. Epilepsia Open, 2017, 2, 90-95.	2.4	11
72	Targeting mitochondrial dysfunction can restore antiviral activity of exhausted HBV-specific CD8 T cells in chronic hepatitis B. Nature Medicine, 2017, 23, 327-336.	30.7	251

#	Article	IF	Citations
73	Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers. Clinical Cancer Research, 2017, 23, 2891-2904.	7.0	122
74	Circulating miRNA landscape identifies miR-1246 as promising diagnostic biomarker in high-grade serous ovarian carcinoma: A validation across two independent cohorts. Cancer Letters, 2017, 388, 320-327.	7.2	73
75	Transcribed ultraconserved region 339 promotes carcinogenesis by modulating tumor suppressor microRNAs. Nature Communications, 2017, 8, 1801.	12.8	36
76	Prognostic but not predictive: focus on stage II right-sided colorectal cancer tumors. Annals of Oncology, 2017, 28, iii101.	1.2	0
77	Radically resected stage III colorectal cancer: sidedness and prognosis. Annals of Oncology, 2017, 28, vill.	1.2	0
78	Focus on metastatic right-sided colon cancer: the best overall response to the first-line non-EGFR treatment correlates with better overall survival. Annals of Oncology, 2017, 28, vi14.	1.2	0
79	Non-Coding RNAs as Predictive Biomarkers to Current Treatment in Metastatic Colorectal Cancer. International Journal of Molecular Sciences, 2017, 18, 1547.	4.1	21
80	Characterisation of peripheral blood mononuclear cell microRNA in early onset psoriatic arthritis. Clinical and Experimental Rheumatology, 2017, 35, 113-121.	0.8	24
81	Peripheral Inflammatory Markers and Antioxidant Response during the Post-Acute and Chronic Phase after Severe Traumatic Brain Injury. Frontiers in Neurology, 2016, 7, 189.	2.4	36
82	In hepatocellular carcinoma miR-494 up-regulates the AKT/mTOR pathway and is involved in Sorafenib resistance. Digestive and Liver Disease, 2016, 48, e28.	0.9	3
83	Integration of gene expression and miRNAs reveals amino acid metabolism as key metabolic hub of adaptation to long term oestrogen deprivation in ER+ breast cancer cells. European Journal of Cancer, 2016, 61, S45.	2.8	0
84	Circulating Non-coding RNA as Biomarkers in Colorectal Cancer. Advances in Experimental Medicine and Biology, 2016, 937, 171-181.	1.6	26
85	Integrating miRNA and gene expression profiling analysis revealed regulatory networks in gastrointestinal stromal tumors. Epigenomics, 2016, 8, 1347-1366.	2.1	23
86	Circulating MicroRNA Quantification Using DNA-binding Dye Chemistry and Droplet Digital PCR. Journal of Visualized Experiments, 2016, , .	0.3	9
87	Serum From Advanced Heart Failure Patients Promotes Angiogenic Sprouting and Affects the Notch Pathway in Human Endothelial Cells. Journal of Cellular Physiology, 2016, 231, 2700-2710.	4.1	20
88	Cerebrospinal fluid amounts of HLA-G in dimeric form are strongly associated to patients with MRI inactive multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 245-249.	3.0	11
89	Persistent infections, immune-senescence and Alzheimer's disease. Oncoscience, 2016, 3, 135-142.	2.2	22
90	Circulating microRNAs found dysregulated in ex-exposed asbestos workers and pleural mesothelioma patients as potential new biomarkers. Oncotarget, 2016, 7, 82700-82711.	1.8	54

#	Article	IF	CITATIONS
91	miRNA array screening reveals cooperative MGMT-regulation between miR-181d-5p and miR-409-3p in glioblastoma. Oncotarget, 2016, 7, 28195-28206.	1.8	34
92	Over-expression of the <i>miR-483-3p</i> overcomes the miR-145/TP53 pro-apoptotic loop in hepatocellular carcinoma. Oncotarget, 2016, 7, 31361-31371.	1.8	45
93	MicroRNA profiles in hippocampal granule cells and plasma of rats with pilocarpine-induced epilepsy – comparison with human epileptic samples. Scientific Reports, 2015, 5, 14143.	3.3	101
94	MicroRNA profiling of primary pulmonary enteric adenocarcinoma in members from the same family reveals some similarities to pancreatic adenocarcinoma—a step towards personalized therapy. Clinical Epigenetics, 2015, 7, 129.	4.1	22
95	Absolute quantification of cell-free microRNAs in cancer patients. Oncotarget, 2015, 6, 14545-14555.	1.8	103
96	An integrated genomic-transcriptomic approach supports a role for the proto-oncogene BCL3 in atherosclerosis. Thrombosis and Haemostasis, 2015, 113, 655-663.	3.4	13
97	The Non-Coding RNA Journal Club: Highlights on Recent Papers. Non-coding RNA, 2015, 1, 87-93.	2.6	3
98	Increase of microRNA-210, Decrease of Raptor Gene Expression and Alteration of Mammalian Target of Rapamycin Regulated Proteins following Mithramycin Treatment of Human Erythroid Cells. PLoS ONE, 2015, 10, e0121567.	2.5	28
99	Circulating microRNAs, miR-939, miR-595, miR-519d and miR-494, Identify Cirrhotic Patients with HCC. PLoS ONE, 2015, 10, e0141448.	2.5	113
100	MicroRNA expression profiling identifies miR-31-5p/3p as associated with time to progression in wild-type RAS metastatic colorectal cancer treated with cetuximab. Oncotarget, 2015, 6, 38695-38704.	1.8	67
101	Long Noncoding RNA Ceruloplasmin Promotes Cancer Growth by Altering Glycolysis. Cell Reports, 2015, 13, 2395-2402.	6.4	105
102	MicroRNAs as biomarker of Parkinson disease?. Neurology, 2015, 84, 636-638.	1.1	10
103	The P2X7 receptor is a key modulator of the PI3K/GSK3 \hat{l}^2 /VEGF signaling network: evidence in experimental neuroblastoma. Oncogene, 2015, 34, 5240-5251.	5.9	149
104	Gene Expression Changes in Progression of Cervical Neoplasia Revealed by Microarray Analysis of Cervical Neoplastic Keratinocytes. Journal of Cellular Physiology, 2015, 230, 806-812.	4.1	49
105	miR-205-5p-mediated downregulation of ErbB/HER receptors in breast cancer stem cells results in targeted therapy resistance. Cell Death and Disease, 2015, 6, e1823-e1823.	6.3	74
106	Age related miRNA signature in mesenchymal progenitors reveals key players in cellular performance and fate. Cytotherapy, $2015,17,S7.$	0.7	0
107	TIMP-1 resistant matrix metalloproteinase-9 is the predominant serum active isoform associated with MRI activity in patients with multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 1121-1130.	3.0	23
108	Association between gene and miRNA expression profiles and stereotyped subset #4 B-cell receptor in chronic lymphocytic leukemia. Leukemia and Lymphoma, 2015, 56, 3150-3158.	1.3	23

#	Article	IF	Citations
109	Diagnostic and prognostic microRNAs in the serum of breast cancer patients measured by droplet digital PCR. Biomarker Research, 2015, 3, 12.	6.8	80
110	Peripheral leukocyte expression of the potential biomarker proteins Bdnf, Sirt1, and Psen1 is not regulated by promoter methylation in Alzheimer's disease patients. Neuroscience Letters, 2015, 605, 44-48.	2.1	32
111	Micromarkers 2.0: an update on the role of microRNAs in cancer diagnosis and prognosis. Expert Review of Molecular Diagnostics, 2015, 15, 1369-1381.	3.1	31
112	Mesenchymal Progenitors Aging Highlights a miR-196 Switch Targeting HOXB7 as Master Regulator of Proliferation and Osteogenesis. Stem Cells, 2015, 33, 939-950.	3.2	56
113	Abstract 142: SiRNA therapy against novel lncRNA NRCP: shutting down the fuel for cancer cells. Cancer Research, 2015, 75, 142-142.	0.9	3
114	Abstract 3964: How to fish a good micro-marker out from a worthless lake: The case of cell-free miR-181a-5p and breast cancer. , 2015, , .		0
115	The 21st century epidemic: infections as inductors of neuro-degeneration associated with Alzheimer's Disease. Immunity and Ageing, 2014, 11, 22.	4.2	30
116	Cellular and Kaposi's sarcoma-associated herpes virus microRNAs in sepsis and surgical trauma. Cell Death and Disease, 2014, 5, e1559-e1559.	6.3	43
117	MicroRNA Expression Profiling and Its Clinical Impact in Breast Cancer. , 2014, , 355-367.		2
118	STAT3-mediated activation of microRNA cluster 17Â92 promotes proliferation and survival of ALK-positive anaplastic large cell lymphoma. Haematologica, 2014, 99, 116-124.	3.5	50
119	Involvement of the Inconstant Bursa of the Fifth Metatarsophalangeal Joint in Psoriatic Arthritis: A Clinical and Ultrasonographic Study. BioMed Research International, 2014, 2014, 1-5.	1.9	6
120	Quantification of Circulating miRNAs by Droplet Digital PCR: Comparison of EvaGreen- and TaqMan-Based Chemistries. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 2638-2642.	2.5	78
121	OncomiR detection in circulating body fluids: a PDMS microdevice perspective. Lab on A Chip, 2014, 14, 4067-4075.	6.0	24
122	573: Epigenetic inactivation of miR-9 family microRNAs in chronic lymphocytic leukemia â^ implications on constitutive activation of NF-κB pathway. European Journal of Cancer, 2014, 50, S138.	2.8	0
123	microRNAome Expression in Chronic Lymphocytic Leukemia: Comparison with Normal B-cell Subsets and Correlations with Prognostic and Clinical Parameters. Clinical Cancer Research, 2014, 20, 4141-4153.	7.0	52
124	Abstract 4785: miR-125b targets erythropoietin and its receptor and their expression correlates with metastatic potential and ERBB2/HER2 expression. , 2014, , .		2
125	Identification of miRNAs Differentially Expressed in Human Epilepsy with or without Granule Cell Pathology. PLoS ONE, 2014, 9, e105521.	2.5	36
126	Genetic subclonal complexity and miR125a-5p down-regulation identify a subset of patients with inferior outcome in low-risk CLL patients. Oncotarget, 2014, 5, 140-149.	1.8	10

#	Article	IF	CITATIONS
127	THU0468â€Up-Regulation of Mir-21 in Peripheral Blood Mononuclear Cells of Early Onset Psoriatic Arthritis: Changes from Baseline after Appropriate Therapy. Annals of the Rheumatic Diseases, 2014, 73, 345.1-345.	0.9	0
128	Abstract 2219: STAT3 network dissection in ALK positive Anaplastic Large Cell Lymphomas. , 2014, , .		0
129	Monocyte chemoattractant protein-1 promoter polymorphism and plasma levels in alzheimer's disease. Immunity and Ageing, 2013, 10, 6.	4.2	18
130	HINCUTs in cancer: hypoxia-induced noncoding ultraconserved transcripts. Cell Death and Differentiation, 2013, 20, 1675-1687.	11.2	99
131	i>CCAT2 $ i>$, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer. Genome Research, 2013, 23, 1446-1461.	5.5	526
132	Epigenetic inactivation of miR-9 family microRNAs in chronic lymphocytic leukemia - implications on constitutive activation of NFκB pathway. Molecular Cancer, 2013, 12, 173.	19.2	66
133	SectionÂ2: Spondyloarthritis. Clinical Drug Investigation, 2013, 33, 95-112.	2.2	0
134	Clinical Monoclonal B Lymphocytosis versus Rai O Chronic Lymphocytic Leukemia: A Comparison of Cellular, Cytogenetic, Molecular, and Clinical Features. Clinical Cancer Research, 2013, 19, 5890-5900.	7.0	60
135	Haplotype of Single Nucleotide Polymorphisms in Exon 6 of the MZF-1 Gene and Alzheimer's Disease. Journal of Alzheimer's Disease, 2013, 34, 439-447.	2.6	5
136	AB0006â€Microrna expression profiles in peripheral blood mononuclear cells of early rheumatoid arthritis. Annals of the Rheumatic Diseases, 2013, 72, A787.3-A787.	0.9	0
137	miR-125b targets erythropoietin and its receptor and their expression correlates with metastatic potential and ERBB2/HER2 expression. Molecular Cancer, 2013, 12, 130.	19.2	73
138	Anti-CD38 Antibody Therapy: Windows of Opportunity Yielded by the Functional Characteristics of the Target Molecule. Molecular Medicine, 2013, 19, 99-108.	4.4	58
139	miR-126&126* Restored Expressions Play a Tumor Suppressor Role by Directly Regulating ADAM9 and MMP7 in Melanoma. PLoS ONE, 2013, 8, e56824.	2.5	80
140	miR-221 affects multiple cancer pathways by modulating the level of hundreds messenger RNAs. Frontiers in Genetics, 2013, 4, 64.	2.3	42
141	First Report of Circulating MicroRNAs in Tumour Necrosis Factor Receptor-Associated Periodic Syndrome (TRAPS). PLoS ONE, 2013, 8, e73443.	2.5	44
142	A tumor-promoting mechanism mediated by retrotransposon-encoded reverse transcriptase is active in human transformed cell lines. Oncotarget, 2013, 4, 2271-2287.	1.8	41
143	miRâ€34a predicts survival of Ewing's sarcoma patients and directly influences cell chemoâ€sensitivity and malignancy. Journal of Pathology, 2012, 226, 796-805.	4.5	128
144	Liver tumorigenicity promoted by microRNA-221 in a mouse transgenic model. Hepatology, 2012, 56, 1025-1033.	7.3	150

#	Article	IF	CITATIONS
145	Principles of MicroRNA Involvement in Breast Cancer. Breast Diseases, 2011, 22, 238-243.	0.0	1
146	MicroRNAs Dysregulation in Human Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 2011, 6, 844-851.	1.1	77
147	MicroRNAs: Toward the Clinic for Breast Cancer Patients. Seminars in Oncology, 2011, 38, 764-775.	2.2	30
148	MicroRNA profiling for the identification of cancers with unknown primary tissueâ€ofâ€origin. Journal of Pathology, 2011, 225, 43-53.	4.5	117
149	Mutated \hat{l}^2 -catenin evades a microRNA-dependent regulatory loop. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 4840-4845.	7.1	48
150	MicroRNA profiling reveals that miR-21, miR486 and miR-214 are upregulated and involved in cell survival in Sézary syndrome. Cell Death and Disease, 2011, 2, e151-e151.	6.3	119
151	MicroRNAs in Cancer (An Overview)., 2011, , 1-71.		0
152	Abstract 167: Identification of miR-34a as a prognostic biomarker of Ewing sarcoma family of tumors. , 2011, , .		0
153	Abstract 150: Regulation of TGFB receptor by miR21 in Sezary syndrome., 2011,,.		0
154	MicroRNA profile in gastrointestinal stromal tumors (GISTs) and correlation with KIT/PDGFRA kinase genotype Journal of Clinical Oncology, 2011, 29, 10056-10056.	1.6	0
155	Resveratrol decreases the levels of miR-155 by upregulating miR-663, a microRNA targeting JunB and JunD. Carcinogenesis, 2010, 31, 1561-1566.	2.8	241
156	Altered miRNA expression in T regulatory cells in course of multiple sclerosis. Journal of Neuroimmunology, 2010, 226, 165-171.	2.3	188
157	Non-coding RNAs change their expression profile after Retinoid induced differentiation of the promyelocytic cell line NB4. BMC Research Notes, 2010, 3, 24.	1.4	27
158	Differential cytogenomics and miRNA signature of the Acute Myeloid Leukaemia Kasumi-1 cell line CD34+38â^' compartment. Leukemia Research, 2010, 34, 1287-1295.	0.8	15
159	Alzheimer's disease gene signature says: beware of brain viral infections. Immunity and Ageing, 2010, 7, 16.	4.2	65
160	Altered glycosylation profile of purified plasma ACT from Alzheimer's disease. Immunity and Ageing, 2010, 7, S6.	4.2	11
161	A transcriptome-wide approach reveals the key contribution of NFI-A in promoting erythroid differentiation of human CD34+ progenitors and CML cells. Leukemia, 2010, 24, 1220-1223.	7.2	17
162	Modulation of mismatch repair and genomic stability by miR-155. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 6982-6987.	7.1	306

#	Article	IF	Citations
163	Oncogenic Role of <i>miR-483-3p</i> at the <i>IGF2/483</i> Locus. Cancer Research, 2010, 70, 3140-3149.	0.9	272
164	Correction: Online Publication Dates for <i>Cancer Research</i> April 15, 2010 Articles. Cancer Research, 2010, 70, 4785-4786.	0.9	0
165	MicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia. Molecular Cancer, 2010, 9, 123.	19.2	107
166	Micromarkers: miRNAs in cancer diagnosis and prognosis. Expert Review of Molecular Diagnostics, 2010, 10, 297-308.	3.1	237
167	Abstract 2087: miR-483-3p is an oncogene involved in nephroblastoma and in adult tumors with activated \hat{l}^2 -catenin. , 2010, , .		0
168	Abstract 2161: Network-based inference of ALK oncogenic signaling in T-cell lymphoproliferative disorders. , 2010, , .		0
169	MicroRNA Fingerprints Identify miR-150 as a Plasma Prognostic Marker in Patients with Sepsis. PLoS ONE, 2009, 4, e7405.	2.5	273
170	MicroRNA-221 Targets Bmf in Hepatocellular Carcinoma and Correlates with Tumor Multifocality. Clinical Cancer Research, 2009, 15, 5073-5081.	7.0	298
171	Altered expression of selected microRNAs in melanoma: Antiproliferative and proapoptotic activity of miRNA-155. International Journal of Oncology, 2009, , .	3.3	30
172	MicroRNA expression changes during human leukemic HL-60 cell differentiation induced by 4-hydroxynonenal, a product of lipid peroxidation. Free Radical Biology and Medicine, 2009, 46, 282-288.	2.9	55
173	MiR-122/Cyclin G1 Interaction Modulates p53 Activity and Affects Doxorubicin Sensitivity of Human Hepatocarcinoma Cells. Cancer Research, 2009, 69, 5761-5767.	0.9	380
174	MicroRNA-221 targets BMF and correlates with tumor multifocality in human hepatocellular carcinoma. Digestive and Liver Disease, 2009, 41, A2.	0.9	0
175	240 MICRORNA-221 TARGETS BMF AND CORRELATES WITH TUMOR MULTIFOCALITY IN HUMAN HEPATOCELLULAR CARCINOMA. Journal of Hepatology, 2009, 50, S97.	3.7	0
176	Karyotype-specific microRNA signature in chronic lymphocytic leukemia. Blood, 2009, 114, 3872-3879.	1.4	179
177	Significance of Aberrant Expression of MicroRNAs in Cancer Cells. , 2009, , 1-12.		0
178	Altered expression of selected microRNAs in melanoma: antiproliferative and proapoptotic activity of miRNA-155. International Journal of Oncology, 2009, 35, 393-400.	3.3	37
179	The methylator phenotype in microsatellite stable colorectal cancers is characterized by a distinct gene expression profile. Journal of Pathology, 2008, 214, 594-602.	4.5	47
180	MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. Oncogene, 2008, 27, 5651-5661.	5.9	619

#	Article	IF	Citations
181	Isolation and characterization of CD146+ multipotent mesenchymal stromal cells. Experimental Hematology, 2008, 36, 1035-1046.	0.4	240
182	MiR-15a and miR-16-1 cluster functions in human leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 5166-5171.	7.1	741
183	Regulation of microRNA Expression: the Hypoxic Component. Cell Cycle, 2007, 6, 1425-1430.	2.6	132
184	MicroRNAs in human cancer: from research to therapy. Journal of Cell Science, 2007, 120, 1833-1840.	2.0	222
185	Tumor Suppressor Functions of <i>ARLTS1</i> in Lung Cancers. Cancer Research, 2007, 67, 7738-7745.	0.9	15
186	Micro-RNA profiling in kidney and bladder cancers. Urologic Oncology: Seminars and Original Investigations, 2007, 25, 387-392.	1.6	566
187	Cyclin G1 Is a Target of miR-122a, a MicroRNA Frequently Down-regulated in Human Hepatocellular Carcinoma. Cancer Research, 2007, 67, 6092-6099.	0.9	782
188	mRNA/microRNA gene expression profile in microsatellite unstable colorectal cancer. Molecular Cancer, 2007, 6, 54.	19.2	240
189	A MicroRNA Signature of Hypoxia. Molecular and Cellular Biology, 2007, 27, 1859-1867.	2.3	990
190	Identification of differentially expressed microRNAs by microarray: A possible role for microRNA genes in pituitary adenomas. Journal of Cellular Physiology, 2007, 210, 370-377.	4.1	203
191	Specific microRNAs are downregulated in human thyroid anaplastic carcinomas. Oncogene, 2007, 26, 7590-7595.	5.9	373
192	Ultraconserved Regions Encoding ncRNAs Are Altered in Human Leukemias and Carcinomas. Cancer Cell, 2007, 12, 215-229.	16.8	681
193	A microRNA expression signature of human solid tumors defines cancer gene targets. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 2257-2261.	7.1	5,220
194	MicroRNA deregulation in human thyroid papillary carcinomas. Endocrine-Related Cancer, 2006, 13, 497-508.	3.1	463
195	MicroRNA Function in Human Hematopoiesis: Identification of Lineage- and Stage-Specific Expression Profiles, Pivotal Targets and Regulatory Circuitries Blood, 2006, 108, 1197-1197.	1.4	0
196	Familial Cancer Associated with a Polymorphism in <i>ARLTS1</i> . New England Journal of Medicine, 2005, 352, 1667-1676.	27.0	119
197	<i>miR-15</i> and <i>miR-16</i> induce apoptosis by targeting BCL2. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 13944-13949.	7.1	3,287
198	Extensive modulation of a set of microRNAs in primary glioblastoma. Biochemical and Biophysical Research Communications, 2005, 334, 1351-1358.	2.1	1,009

#	ARTICLE	IF	CITATIONS
199	MicroRNA Gene Expression Deregulation in Human Breast Cancer. Cancer Research, 2005, 65, 7065-7070.	0.9	3,719
200	A MicroRNA Signature Associated with Prognosis and Progression in Chronic Lymphocytic Leukemia. New England Journal of Medicine, 2005, 353, 1793-1801.	27.0	2,255
201	An oligonucleotide microchip for genome-wide microRNA profiling in human and mouse tissues. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 9740-9744.	7.1	906
202	MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 11755-11760.	7.1	1,238
203	The Role of Micro-RNAs in Rheumatic Diseases: An Update. , 0, , .		1
204	Comparison of whole-genome expression analysis in patients with secondary adrenal insufficiency treated with conventional treatment versus modified-release hydrocortisone. Endocrine Abstracts, 0,	0.0	0